Literature DB >> 36155782

SYNPRED: prediction of drug combination effects in cancer using different synergy metrics and ensemble learning.

António J Preto1,2, Pedro Matos-Filipe1, Joana Mourão3, Irina S Moreira4,3.   

Abstract

BACKGROUND: In cancer research, high-throughput screening technologies produce large amounts of multiomics data from different populations and cell types. However, analysis of such data encounters difficulties due to disease heterogeneity, further exacerbated by human biological complexity and genomic variability. The specific profile of cancer as a disease (or, more realistically, a set of diseases) urges the development of approaches that maximize the effect while minimizing the dosage of drugs. Now is the time to redefine the approach to drug discovery, bringing an artificial intelligence (AI)-powered informational view that integrates the relevant scientific fields and explores new territories.
RESULTS: Here, we show SYNPRED, an interdisciplinary approach that leverages specifically designed ensembles of AI algorithms, as well as links omics and biophysical traits to predict anticancer drug synergy. It uses 5 reference models (Bliss, Highest Single Agent, Loewe, Zero Interaction Potency, and Combination Sensitivity Score), which, coupled with AI algorithms, allowed us to attain the ones with the best predictive performance and pinpoint the most appropriate reference model for synergy prediction, often overlooked in similar studies. By using an independent test set, SYNPRED exhibits state-of-the-art performance metrics either in the classification (accuracy, 0.85; precision, 0.91; recall, 0.90; area under the receiver operating characteristic, 0.80; and F1-score, 0.91) or in the regression models, mainly when using the Combination Sensitivity Score synergy reference model (root mean square error, 11.07; mean squared error, 122.61; Pearson, 0.86; mean absolute error, 7.43; Spearman, 0.87). Moreover, data interpretability was achieved by deploying the most current and robust feature importance approaches. A simple web-based application was constructed, allowing easy access by nonexpert researchers.
CONCLUSIONS: The performance of SYNPRED rivals that of the existing methods that tackle the same problem, yielding unbiased results trained with one of the most comprehensive datasets available (NCI ALMANAC). The leveraging of different reference models allowed deeper insights into which of them can be more appropriately used for synergy prediction. The Combination Sensitivity Score clearly stood out with improved performance among the full scope of surveyed approaches and synergy reference models. Furthermore, SYNPRED takes a particular focus on data interpretability, which has been in the spotlight lately when using the most advanced AI techniques.
© The Author(s) 2022. Published by Oxford University Press GigaScience.

Entities:  

Keywords:  biophysics; cancer; drug synergy; ensemble learning; interpretability; omics

Mesh:

Substances:

Year:  2022        PMID: 36155782      PMCID: PMC9511701          DOI: 10.1093/gigascience/giac087

Source DB:  PubMed          Journal:  Gigascience        ISSN: 2047-217X            Impact factor:   7.658


  63 in total

1.  A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor.

Authors:  Marco P Licciardello; Anna Ringler; Patrick Markt; Freya Klepsch; Charles-Hugues Lardeau; Sara Sdelci; Erika Schirghuber; André C Müller; Michael Caldera; Anja Wagner; Rebecca Herzog; Thomas Penz; Michael Schuster; Bernd Boidol; Gerhard Dürnberger; Yasin Folkvaljon; Pär Stattin; Vladimir Ivanov; Jacques Colinge; Christoph Bock; Klaus Kratochwill; Jörg Menche; Keiryn L Bennett; Stefan Kubicek
Journal:  Nat Chem Biol       Date:  2017-05-22       Impact factor: 15.040

2.  An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies.

Authors:  Jennifer O'Neil; Yair Benita; Igor Feldman; Melissa Chenard; Brian Roberts; Yaping Liu; Jing Li; Astrid Kral; Serguei Lejnine; Andrey Loboda; William Arthur; Razvan Cristescu; Brian B Haines; Christopher Winter; Theresa Zhang; Andrew Bloecher; Stuart D Shumway
Journal:  Mol Cancer Ther       Date:  2016-03-16       Impact factor: 6.261

Review 3.  Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects.

Authors:  Mariana Brandão; Noam F Pondé; Francesca Poggio; Nuria Kotecki; Mauren Salis; Matteo Lambertini; Evandro de Azambuja
Journal:  Expert Rev Anticancer Ther       Date:  2018-05-24       Impact factor: 4.512

Review 4.  UTX Mutations in Human Cancer.

Authors:  Lu Wang; Ali Shilatifard
Journal:  Cancer Cell       Date:  2019-02-11       Impact factor: 31.743

5.  Systematic Quantification of Population Cell Death Kinetics in Mammalian Cells.

Authors:  Giovanni C Forcina; Megan Conlon; Alex Wells; Jennifer Yinuo Cao; Scott J Dixon
Journal:  Cell Syst       Date:  2017-06-07       Impact factor: 10.304

6.  SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets.

Authors:  Shuyu Zheng; Wenyu Wang; Jehad Aldahdooh; Alina Malyutina; Tolou Shadbahr; Ziaurrehman Tanoli; Alberto Pessia; Jing Tang
Journal:  Genomics Proteomics Bioinformatics       Date:  2022-01-24       Impact factor: 7.691

7.  DeepSynergy: predicting anti-cancer drug synergy with Deep Learning.

Authors:  Kristina Preuer; Richard P I Lewis; Sepp Hochreiter; Andreas Bender; Krishna C Bulusu; Günter Klambauer
Journal:  Bioinformatics       Date:  2018-05-01       Impact factor: 6.937

8.  Dynamic Targeting in Cancer Treatment.

Authors:  Zhihui Wang; Thomas S Deisboeck
Journal:  Front Physiol       Date:  2019-02-14       Impact factor: 4.566

9.  Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model.

Authors:  Bhagwan Yadav; Krister Wennerberg; Tero Aittokallio; Jing Tang
Journal:  Comput Struct Biotechnol J       Date:  2015-09-25       Impact factor: 7.271

10.  SPOTONE: Hot Spots on Protein Complexes with Extremely Randomized Trees via Sequence-Only Features.

Authors:  A J Preto; Irina S Moreira
Journal:  Int J Mol Sci       Date:  2020-10-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.